Related Experiment Video

Updated: Jul 6, 2026

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled

Craig I Coleman, Kurt Reinhart, Jeffrey Kluger

    Current Medical Research and Opinion
    |April 4, 2008
    PubMed
    Abstract

    Insights

    Statins do not significantly impact the risk of developing new-onset type 2 diabetes mellitus. This meta-analysis of randomized controlled trials found no statistically significant increase or decrease in diabetes risk associated with statin use.

    Area of Science:

    • Cardiovascular Medicine
    • Endocrinology
    • Pharmacology

    Background:

    • Statins are widely prescribed lipid-lowering drugs.
    • The potential impact of statins on glucose metabolism and diabetes risk requires thorough investigation.
    • This meta-analysis examines the effect of statins on new-onset type 2 diabetes mellitus.

    Discussion:

    • The pooled analysis of five randomized controlled trials (n=39,791) revealed no significant alteration in the risk of developing new-onset type 2 diabetes mellitus with statin use (RR, 1.03; 95% CI, 0.89-1.19).
    • Statistical heterogeneity was observed, with pravastatin showing a trend towards risk reduction and other statins a trend towards risk increase.
    • Publication bias could not be excluded based on the funnel plot analysis.

    Key Insights:

    • Statins, as a drug class, do not significantly increase or decrease the risk of new-onset type 2 diabetes mellitus.
    • Individual statins may have differential effects on diabetes risk, warranting further research.
    • The overall evidence suggests a neutral effect of statin therapy on incident diabetes.

    Outlook:

    • Further research is needed to explore potential differential effects of specific statins on diabetes risk.
    • Investigating the mechanisms underlying statin-associated glucose metabolism changes is crucial.
    • Clinical guidelines should consider these findings when assessing the overall risk-benefit profile of statin therapy.

    Related Concept Videos

    Type II Diabetes I: Introduction01:26

    Type II Diabetes I: Introduction

    Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
    Diabetes Mellitus: Type 2 and Gestational01:22

    Diabetes Mellitus: Type 2 and Gestational

    Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Type II Diabetes II: Pathophysiology01:24

    Type II Diabetes II: Pathophysiology

    PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
    Carbohydrate Metabolism01:36

    Carbohydrate Metabolism

    Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
    Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...